This study besides being crucial for the advancement in the knowledge of the basic mechanisms underlying Dravet syndrome and many other forms of epilepsy as well, raises in the meanwhile the question of the need to design different therapies in relation to the Nav1.1 epileptogenic affected gene. The gene discussed is SCN1A; the disease is encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.